TEL AVIV, Israel, Aug. 28, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company
focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced it will
provide a corporate overview at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright &
Co., LLC. The conference is being held on September 10-12, 2017 at Lotte New York Palace Hotel in New York City.
Presentation Details:
Date: Monday, September 11, 2017
Time: 2:35-3:00 PM Eastern Time
Location: Holmes II; Lotte New York Palace Hotel in New York City
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery,
development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate,
ofranergene obadenovec (VB-111), is a first-in-class biologic agent that uses a dual mechanism to target solid tumors. It utilizes
an angiogenesis-specific sensor (VBL's PPE-1-3x proprietary promoter) to specifically target the tumor vasculature, by induction of
cell death in angiogenic endothelial cells in the tumor milieu. Moreover, it is an immune-stimulant that triggers a local
anti-tumor immune response, which is accompanied by recruitment of CD8 T-cells and apoptosis of tumor cells. Ofranergene obadenovec
is positioned to treat a wide range of solid tumors and is conveniently administered as an IV infusion once every two months. It
has been observed to be well-tolerated in >300 cancer patients and we have observed its efficacy signals in an “all comers”
Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3
pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).
INVESTOR CONTACT: Michael Rice LifeSci Advisors, LLC mrice@lifesciadvisors.com (646) 597-6979 MEDIA CONTACT: Matt Middleman, M.D. LifeSci Public Relations matt.middleman@lifescipublicrelations.com (646) 627-8384
